Weight loss medications approved by the FDA specifically for chronic weight management include semaglutide (Wegovy) and tirzepatide (Zepbound)
Furthermore, these medications are administered through oral, injectable, and other routes
Some potential risks of not stopping include: Drug interactions with surgical anesthesia Increased bleeding risk Changes in blood sugar levels Each of these issues may lead to further complications
The Ministry of Food and Drug Safety has emphasized that even when used within its approved scope, Wegovy can be accompanied by side effects such as headaches, constipation, hair loss, gallstones, and acute pancreatitis.
The retatrutide factor For researchers who have plateaued on both semaglutide and tirzepatide, retatrutide represents the next frontier
The synergistic blend of these ingredients supports skin brightening and overall vitality